Cancers don't sleep: The Myc oncogene can disrupt circadian rhythm

April 9, 2013, University of Pennsylvania School of Medicine

The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells. Postdoctoral fellow Brian Altman, PhD, and graduate student Annie Hsieh, MD, both from the in the lab of Chi Van Dang, MD, PhD, director of the Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, present their data in the "Metabolic Pathway Regulation in Cancer" session at the 2013 American Association for Cancer Research meeting, Washington, D.C., April 9, 2013.

Timing of the body's molecular clock in normal cells synchronizes the cellular need for energy with food intake during our sleep-wake cycle. Timing matters to the study of cancer in two ways. First, toxicity to some is related to time of day. For example, a cancer drug called 5-flourouracil is less toxic if given to a patient at night because the that detoxify it are more abundant at night.

Second, several circadian rhythm genes have been implicated as tumor suppressors, although those exact connections are as yet unclear. Other researchers have also observed that many, but not all, cancer lack proper circadian rhythm.

"Our hypothesis is that disrupting circadian rhythm benefits cancer cells by unleashing their metabolism from the constraints of the molecular clock," says Altman. "In this regard, cancers don't sleep; they don't rest."

The Penn study deals with the relationship of clock proteins in associated with three types of cancer cells. The researchers surmise that Myc may affect circadian rhythm by promiscuously binding to promoter regions in key genes for maintaining circadian rhythm. In fact, using a well known genome browser they confirmed that Myc binds to circadian genes.

The Penn team also found that Myc upregulates another clock-regulated protein called NAMPT, potentially leading to dysregulated Sirt1 activity, another protein that is part of the complicated .

Inhibiting NAMPT downstream of Myc also led to changes in circadian gene expression, suggesting a role for the modulation of other proteins downstream of Myc in throwing a wrench in the clock's gears.

Using cells from cultures of neuroblastoma, osteosarcoma, and hepatocellular carcinoma, which all overexpress Myc, they found that the abundance of Myc specifically upregulated the circadian protein Rev-erbα. This protein in turn suppressed the oscillation of Bmal1 messenger RNA and decreased expression of the main clock protein Bmal1.

What's more, the disrupted circadian oscillations in the Myc-expressing could be partially rescued by inhibiting expression of Rev-erbα.

"Our data suggest that Myc-driven cancers have altered circadian oscillation due to upregulation of Rev-erbα and NAMPT, and that these Myc cancers may be good candidates for chronotherapy," says Altman. "This work ties together the study of cell metabolism and cancer chronotherapy – If cells don't have to 'rest," they may replicate all the time, with no breaks at all. "

"The understanding of these basic mechanisms from our work should lead to better treatment strategies that reduce side effects and increase effectiveness" says Hsieh.

Explore further: Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model

More information: This study was funded by the National Cancer Institute (R01CA051497, R01CA57341) and the Leukemia and Lymphoma Society (636311).

Related Stories

Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model

November 13, 2012
The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a ...

Coordinating the circadian clock: Researchers find that molecular pair controls time-keeping and fat metabolism

April 4, 2012
(PhysOrg.com) -- The 24-hour internal clock controls many aspects of human behavior and physiology, including sleep, blood pressure, and metabolism. Disruption in circadian rhythms leads to increased incidence of many diseases, ...

Major cancer protein amplifies global gene expression

September 27, 2012
Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth. A study carried out by researchers at the National Institutes ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.